Analyst Review Alert: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

The shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) currently has mean rating of 1.73 while 6 analysts have recommended the shares as “BUY”, 7 recommended as “OUTPERFORM” and 2 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The means estimate of sales for the year ending Dec-16 is 1.68 million by 14 analysts.

The mean price target for the shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is at 98.14 while the highest price target suggested by the analysts is 125.00 and low price target is 66.00. The mean price target is calculated keeping in view the consensus of 14 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stands at -1.45 while the EPS for the current year is fixed at -5.84 by 15 analysts.

The next one year’s EPS estimate is set at -6.01 by 15 analysts while a year ago the analysts suggested the company’s EPS at -5.84.

In its latest quarter ended on 31^st March 2016, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) reported earnings of -$1.35. The posted earnings missed the analyst’s consensus by -$0.06 with the surprise factor of -4.70%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of adult inoperable tumor-induced osteomalacia patients. Its biologics product candidates also comprise recombinant human beta-glucuronidase (rhGUS), an intravenous enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy in preclinical development for galactosialidosis. In addition, the company is developing a range of small-molecule product candidates comprising UX007, a substrate replacement therapy in a Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid in a Phase II extension study to treat hereditary inclusion body myopathy. It has collaboration and license agreement with Nobelpharma Co., Ltd., Kyowa Hakko Kirin Co. Ltd., and Nobelpharma Co., Ltd.; and license agreements with Saint Louis University, AAI Pharma Services Corp., HIBM Research Group, St. Jude Children’s Research Hospital, and Baylor Research Institute. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.